Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

May 1, 2026

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

May 1, 2026

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

May 1, 2026

Birdfy’s smart bird feeder is down to its best-ever price for Mother’s Day

May 1, 2026

Whitespace Makes Iris, AI Intelligence Analysis Agent, Generally Available to Authorized DoW and IC Users

May 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » EOSE 4-DAY DEADLINE ALERT: Eos Energy (EOSE) Facing Securities Class Action Alleging Misstatements on Production Scale, Guidance – Hagens Berman
Press Release

EOSE 4-DAY DEADLINE ALERT: Eos Energy (EOSE) Facing Securities Class Action Alleging Misstatements on Production Scale, Guidance – Hagens Berman

By News RoomMay 1, 20263 Mins Read
EOSE 4-DAY DEADLINE ALERT: Eos Energy (EOSE) Facing Securities Class Action Alleging Misstatements on Production Scale, Guidance – Hagens Berman
Share
Facebook Twitter LinkedIn Pinterest Email

SAN FRANCISCO, May 01, 2026 (GLOBE NEWSWIRE) — Hagens Berman, a leading global shareholder rights law firm, today issued an updated notice to investors in Eos Energy Enterprises, Inc. (NASDAQ: EOSE) regarding the pending securities class action lawsuit. Investors who purchased EOSE and suffered losses between November 5, 2025, and February 26, 2026, have until May 5, 2026, to move the court for appointment as Lead Plaintiff.

SUBMIT YOUR LOSSES TO HAGENS BERMAN

The EOSE Class Action: The Allegedly False Automated Production Narrative

The litigation against Eos Energy centers on allegations that the company misrepresented its ability to scale production of its zinc-based battery systems at its Turtle Creek facility. Throughout late 2025, management repeatedly touted a transition to a fully automated manufacturing line and affirmed revenue guidance of $150 million to $160 million.

However, on February 26, 2026, Eos revealed that its fiscal year 2025 revenue was only $114.2 million—missing its own guidance by over 25%. The company finally admitted to systemic operational failures that were previously concealed from the market:

  • Excessive Equipment Downtime: Battery line downtime ran in the mid-30% range, more than triple the industry benchmark of 10%.
  • Automation Yield Failures: Automated bipolar production failed to hit quality targets, leading to costly rework cycles and lost output.
  • Management Transparency: Analysts have since questioned how management could confidently reiterate targets as late as November 2025 while these manufacturing problems were already known internally.

Stock Impact and Investor Action

Following these disclosures, Eos Energy’s stock price plummeted 39.4% in a single day, falling from $11.13 to $6.74, erasing over $1.4 billion in market capitalization.

“We are specifically investigating exactly when Eos management became aware that the automated line was failing to meet its design intent,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the claims alleged in the pending suit.

If you purchased EOSE securities during the class period and have substantial losses, you are urged to contact the firm now to discuss your rights before the May 5, 2026 deadline.

DEEP DIVE ANALYIS: Visit Hagens Berman’s dedicated EOSE case page: www.hbsslaw.com/cases/eos-energy, or view our latest video summary of the allegations: https://youtu.be/FBBIlvb_BS0

Whistleblowers: Persons with non-public information regarding Eos should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/1fd57ebb-c302-42af-8064-c0abda8c1e23

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/65886ef1-1fe6-4f5f-97b3-90b0a4957880

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

Whitespace Makes Iris, AI Intelligence Analysis Agent, Generally Available to Authorized DoW and IC Users

Based Eggman Announces Stage 3 Presale Progress

Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences

Investment Banking and Trading Services Market Analysis Report 2026: Bulge-Bracket Banks vs. Elite Boutiques

Shares, Opportunities and Strategies in the $1.7 Billion Ice Cream Maker Market, 2026-2035

Experts Highlight What Parents Need to Know About Child and Adolescent Mental Health

Editors Picks

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

May 1, 2026

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

May 1, 2026

Birdfy’s smart bird feeder is down to its best-ever price for Mother’s Day

May 1, 2026

Whitespace Makes Iris, AI Intelligence Analysis Agent, Generally Available to Authorized DoW and IC Users

May 1, 2026

Latest News

Based Eggman Announces Stage 3 Presale Progress

May 1, 2026

Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences

May 1, 2026

Investment Banking and Trading Services Market Analysis Report 2026: Bulge-Bracket Banks vs. Elite Boutiques

May 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version